

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>245553US0CONT</b>		SERIAL NO. <b>10/743,997</b>	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT <b>Yukio NIHEI, et al.</b>			
				FILING DATE <b>December 24, 2003</b>		GROUP <b>1618</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,525,632	06/11/1996	OBSUMI, et al.			
	AB	5,731,353	03/24/1998	OHSUMI, et al.			
	AC	5,674,906	10/07/1997	HATANAKA, et al.			
	AD	6,462,087	10/08/2002	MORINAGA, et al.			
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES                  NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AW	HIDEKI, H., et al., "Influence of the Steroid Agent on Cytotoxicity of the Antitumor Agent -Examination in the Human Culture Cell Line-," 120 <sup>th</sup> Annual Meeting of the Pharmaceutical Society of Japan, Summary 4, March 5, 2000, page 83 with English translation					
	AX	IWASAKI, S., et al., "Natural Organic Compounds that Affect to Microtubule Functions: Synthesis and Structure-Activity Relationships of Combretastatins, Curacin A and Their Analogs as the Colchicine-site Ligands on Tubulin," Yakugaku Zasshi, Journal of the Pharmaceutical Society of Japan, Vol.120, No. 10, October 1, 2000, pages 875-889					
	AY	KIM, T. J., et al., "Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma," Cancer Res 67:(19), October 1, 2007, pages 9337-9345					
	AZ	OHNO, T., et al., "Antitumor and Antivascular Effects of AC-7700, A Combretastatin A-4 Derivative, Against Rat Liver Cancer, Int J Clin, 7, June 2002, pages 171-176				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner							
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.  245553US0CONT		SERIAL NO.  10/743,997	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Yukio NIHEI, et al.			
				FILING DATE  December 24, 2003		GROUP  1618	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAA	HORI, K., et al., "A Novel Combretastatin A-4 Derivative, AC7700, Strongly Stanches Tumour Blood Flow and Inhibits Growth of Tumors Developing in Various Tissues and Organs," British Journal of Cancer, 86, May 20, 2002, pages 1604-1614					
	AAB	HORI, K., et al., "Stoppage of Blood flow in 3-methylcholanthrene-induced Autochthonous Primary Tumor Due to a Novel Combretastatin A-4 Derivative, AC7700, and its Antitumor Effect," Med Sci Monit, 7(1), Jan-Feb 2001, pages 26-33					
	AAC	NIHEI, Y., et al., "A Novel Combretastatin A-4 Derivatives, AC-7700, Shows Marked Antitumor Activity Against Advanced Solid Tumors and Orthotopically Transplanted," Jpn. J. Cancer Res., September 1999, 90, pages 1016-1025					
	AAD	HORI, K., et al., "Tumor Blood Flow Interruption After Radiotherapy Strongly Inhibits Tumor Regrowth," Cancer Sci, Vol. 99, No. 7, July 2008, pages 1485-1491					
	AAE	HORI, K., et al., "Differential Relationship Between Changes in Tumour Size and Microcirculatory Functions Induced by Therapy with an Antivascular Drug and with Cytotoxic Drugs: Implications for the Evaluation of Therapeutic Efficacy of AC7700 (AVE8062), European Journal of Cancer, 39 (13), September 2003, pages 1957-1966					
	AAF	MORINAGA, Y. et al., "Combination Effect of AC-7700, A Novel Combretastatin A-4 Derivative, and Cisplatin Against Murine and Human Tumors In Vivo," Cancer Sci, Vol. 94, No. 2, 2003, pages 200-204					
	AAG	LAVISSE, S., et al., "Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography," Investigative Radiology, Vol. 43, No. 2, February 2008, pages 100-111					
	AAH	HORI, K., et al., "Microvascular Mechanisms by Which the Combretastatin A-4 Derivative AC7700 (AVE8062) Induces Tumour Blood Flow Stasis," British Journal of Cancer, 89(7), October 6, 2003, pages 1334-1344					
	AAI	NIHEI, Y., et al., "Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy," Jpn. J. Cancer Res., 90(12), December 1999, pages 1387-1395					
	AAJ	HORI, K., et al., "Antitumor Effects Due to Irreversible Stoppage of Tumor Tissue Blood Flow: Evaluation of a Novel Combretastatin A-4 Derivative, AC7700, Jpn. J. Cancer Res., 90, September 1999, pages 1026-1038					
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							